Eric Schwaber
Internal Medicine · Milford, CTNPI 1528598364
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,400 of the $6,491 with a category attached, or 83.2%. GSK accounts for 84.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $5,688 and has fallen 92.8% since, to $412 in 2025. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $118.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- AbbVie$424
- Inspire Medical Systems, Inc.$291
- Novo Nordisk$113
- Exact Sciences$73
- AstraZeneca$67
- plus $63 from 3 others
What the payments were for
- Consulting fees$5,40083%
- Food & beverage$1,09117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $5,460 |
| AbbVie | 22 | $424 |
| Inspire Medical Systems, Inc. | 9 | $291 |
| Novo Nordisk | 5 | $113 |
| Exact Sciences | 3 | $73 |
| AstraZeneca | 3 | $67 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Amgen | 1 | $20 |
| Almatica Pharma LLC | 1 | $14 |
How this compares
$6,491 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 111 | $173,079 |
| MounjaroTirzepatide | 75 | $94,409 |
| EliquisApixaban | 60 | $86,778 |
| OzempicSemaglutide | 61 | $77,868 |
| RybelsusSemaglutide | 15 | $35,184 |
| MyrbetriqMirabegron | 37 | $24,907 |
| JanuviaSitagliptin Phosphate | 16 | $21,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,446 |
| FarxigaDapagliflozin Propanediol | 15 | $17,335 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $14,329 |
| TrulicityDulaglutide | 13 | $13,073 |
| Arnuity ElliptaFluticasone Furoate | 51 | $11,506 |
| Serevent DiskusSalmeterol Xinafoate | 15 | $8,396 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $7,851 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $7,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $113 | $113,05276 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $5,460 | $45,28294 claims |
| AstraZenecaFarxiga | $67 | $17,33515 claims |
| AbbVieSynthroid | $424 | $4,32657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Milford
- Steven SaundersMilford$49K
- Gary SpectorMilford$32K
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Charles MontanoCromwell$970K
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Jeffrey KatzOxford$361K
- Nicholas DainiakBridgeport$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.